Xintela AB (Sweden) Performance
| XINT Stock | SEK 0.33 0.01 3.13% |
The firm maintains a market beta of -0.92, which attests to possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Xintela AB are expected to decrease slowly. On the other hand, during market turmoil, Xintela AB is expected to outperform it slightly. At this point, Xintela AB has a negative expected return of -0.47%. Please make sure to check out Xintela AB's maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Xintela AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Xintela AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 33.6 M | |
| Total Cashflows From Investing Activities | -1.2 M | |
| Free Cash Flow | -44.1 M |
Xintela |
Xintela AB Relative Risk vs. Return Landscape
If you would invest 48.00 in Xintela AB on September 24, 2024 and sell it today you would lose (15.00) from holding Xintela AB or give up 31.25% of portfolio value over 90 days. Xintela AB is generating negative expected returns and assumes 4.5036% volatility on return distribution over the 90 days horizon. Simply put, 40% of stocks are less volatile than Xintela, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Xintela AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xintela AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xintela AB, and traders can use it to determine the average amount a Xintela AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1053
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XINT |
Estimated Market Risk
| 4.5 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Xintela AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xintela AB by adding Xintela AB to a well-diversified portfolio.
Xintela AB Fundamentals Growth
Xintela Stock prices reflect investors' perceptions of the future prospects and financial health of Xintela AB, and Xintela AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xintela Stock performance.
| Return On Equity | -4.69 | |||
| Return On Asset | -1.14 | |||
| Current Valuation | 122.93 M | |||
| Shares Outstanding | 307.57 M | |||
| Price To Earning | (4.40) X | |||
| Price To Book | 11.52 X | |||
| Price To Sales | 5,115 X | |||
| EBITDA | (54.43 M) | |||
| Cash And Equivalents | 11.14 M | |||
| Cash Per Share | 0.53 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (42.89 M) | |||
| Earnings Per Share | (0.73) X | |||
| Total Asset | 24.74 M | |||
About Xintela AB Performance
Assessing Xintela AB's fundamental ratios provides investors with valuable insights into Xintela AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Xintela AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Xintela AB , a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company was founded in 2009 and is based in Lund, Sweden. Xintela AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 13 people.Things to note about Xintela AB performance evaluation
Checking the ongoing alerts about Xintela AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xintela AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xintela AB generated a negative expected return over the last 90 days | |
| Xintela AB has some characteristics of a very speculative penny stock | |
| Xintela AB has high historical volatility and very poor performance | |
| Xintela AB has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (58.39 M) with profit before overhead, payroll, taxes, and interest of 2.08 M. | |
| Xintela AB has accumulated about 11.14 M in cash with (42.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 59.0% of the company outstanding shares are owned by insiders |
- Analyzing Xintela AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xintela AB's stock is overvalued or undervalued compared to its peers.
- Examining Xintela AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xintela AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xintela AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xintela AB's stock. These opinions can provide insight into Xintela AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Xintela Stock Analysis
When running Xintela AB's price analysis, check to measure Xintela AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xintela AB is operating at the current time. Most of Xintela AB's value examination focuses on studying past and present price action to predict the probability of Xintela AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xintela AB's price. Additionally, you may evaluate how the addition of Xintela AB to your portfolios can decrease your overall portfolio volatility.